PD-L1-IN-2_product_DataBase

Bioactivity	PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research[1].
Invitro	PD-L1-IN-2 对 RKO 细胞的抑制作用IC50值为 31.7μM[1]。PD-L1-IN-2 (0-10 μM; 0-24 hours) 抑制 RKO 细胞中 PD-L1 表达呈剂量依赖性和时间依赖性[1]。PD-L1-IN-2 (0-10 μM; 0-24 hours) 促进 PD-L1 蛋白的周转。在 CHX 脉冲追逐中，PD-L1-IN-2 处理的细胞中 PD-L1 周转率比未处理的细胞要快[1]. Western Blot Analysis[1] Cell Line:
In Vivo	PD-L1-IN-2 (i.p.; 25/50 mg/kg; once a day; 16 days) 可使肿瘤减小，50 mg/kg 组的抑制率为 45%，50 mg/kg 组的平均肿瘤重量显著低于PBS组[1]。 Animal Model:
Name	PD-L1-IN-2
CAS	2894733-91-4
Formula	C33H38N4O6
Molar Mass	586.68
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Pan-Pan Fu, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66(8):5427-5438.

PeptideDB